Abattis Bioceuticals Corp.: Northern Vine Begins Security Build
October 6, 2015 (Source: Abattis Bioceuticals Corp.) — Northern Vine Canada Inc. (“Northern Vine”), a subsidiary of Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTCQX: ATTBF) (CSE: ATT), would like to announce that work has been initiated to complete the leasehold improvements for Northern Vine in support of its application for a Controlled Substance License.
Northern Vine has applied for a Controlled Drugs and Substances Dealer’s License. This process includes an in-depth application in accordance with the Narcotic Control Regulations, including:
- Physical security
- Activities & substances
- Record keeping
The pending Northern Vine application for a Controlled Drugs and Substances Dealer’s License is currently under review. The Company is in the process of completing all leasehold improvements to meet the specified security requirements; once all the outstanding items are complete, we will arrange an inspection to confirm that the security is in compliance with the requirements for Controlled Substances.
Northern Vine Canada Inc.
Northern Vine has applied for a Controlled Substances License from Health Canada. The Controlled Substances License will enable the Company to perform quality testing on all pharmaceutical-grade products to import, export and handle controlled substances (such as Cannabis and Cannabis products) as well as act as a formulation and compounding pharmacy to produce differentiating products and delivery systems.
Northern Vine has produced pharmaceutical, health, and skin care products, as well as medical diagnostics and drug delivery systems. It had a GMP certified lab in Langley, BC that has been repurposed for a Controlled Substances License operation. Northern Vine has had a focus on R&D, testing, packaging and shipment of pharmaceutical grade drugs, bioceuticals, nutraceuticals and cosmetics (not currently including cannabis and cannabis-derived products), soft gelatin capsules and custom-formulated softgels for private label manufacturers. The facility is one of only three gel cap production facilities in BC and has its own filling, labeling and packaging equipment. The license allows for the addition of two-piece capsule and tablet equipment. Northern Vine is also the holder of 15 Health Canada natural health product licenses.
Get our daily investorintel update
Northern Vine plans to conduct R&D on medical grade marijuana for use in pain alleviation, pharmaceuticals, sprays, creams, and tinctures that it plans to patent.
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company that aggregates, incubates, integrates, and invests in the botanical drug development industry. The Company develops and licenses natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets – some of which will contain cannabinoid compounds. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at:www.abattis.com.
ON BEHALF OF THE BOARD
Bill Fleming, CEO
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.
Raj Shah has professional experience working for over a half a dozen years at financial firms such as Merrill Lynch and First Allied Securities Inc., ... <Read more about Raj Shah>